Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Medullary 1

Interventions

vandetanib 9cabozantinib 6selpercatinib 4Sorafenib 3Sunitinib 2Magnetic Resonance Spectroscopy 2yeast-CEA vaccine 1tanespimycin 1rovalpituzumab tesirine 1pralsetinib 1pembrolizumab 1pazopanib 1lenvatinib 1Vorinostat 1Temozolomide 1Specimen Handling 1Pharmacogenomic Testing 1Nivolumab 1Lithium Carbonate 1Irinotecan 1Gefitinib 1Ferrosoferric Oxide 1Dexamethasone 1Capecitabine 1Bortezomib 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Medullary × yeast-CEA vaccine × Clear all
NCT01856920 2024-07-09

QUILT-3.006 for Recurrent Medullary Thyroid Cancer

NantCell, Inc.

Phase 2 Completed
35 enrolled 9 charts

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡